Relmacabtagene Autoleucel

BIOLOGICAL4 trials

Sponsors

Peking University Cancer Hospital & Institute, Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions

B-cell LymphomaFollicular LymphomaFollicular Lymphoma Grade 3BHigh-grade B-cell LymphomaLarge B-cell LymphomaLymphoma, B-CellLymphoma, Large B-Cell, DiffuseMediastinal B-Cell Diffuse Large Cell Lymphoma

Phase 2

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Peking University Cancer Hospital & InstituteB-cell Lymphoma

Start: 2023-01-03End: 2024-12-10Target: 20Updated: 2024-01-08

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Active, not recruitingNCT06093841

Shanghai Ming Ju Biotechnology Co., Ltd.Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse +1

Start: 2023-11-03End: 2029-11-04Target: 46Updated: 2025-02-11

Unknown Phase

Relmacabtagene Autoleucel in Patients With LBCL

Shanghai Ming Ju Biotechnology Co., Ltd.Large B-cell Lymphoma

Start: 2022-12-28End: 2024-12-31Target: 200Updated: 2024-03-28

Relmacabtagene Autoleucel in Hematologic Malignancies

Not yet recruitingNCT06142188

Shanghai Ming Ju Biotechnology Co., Ltd.Follicular Lymphoma, Large B-cell Lymphoma, Lymphoma, B-Cell

Start: 2023-12-28End: 2038-12-31Target: 150Updated: 2023-11-21